Last reviewed · How we verify
lidocainhydrochlorid
lidocainhydrochlorid is a Small molecule drug developed by Kai Henrik Wiborg Lange. It is currently in Phase 1 development. Also known as: Lidocaine, Xylocaine.
Lidocaine hydrochloride is a medication used to treat pain, specifically in the context of a continuous peripheral nerve block. It is administered in a solution, often in combination with isotonic saline, for this purpose.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | lidocainhydrochlorid |
|---|---|
| Also known as | Lidocaine, Xylocaine |
| Sponsor | Kai Henrik Wiborg Lange |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lidocainhydrochlorid CI brief — competitive landscape report
- lidocainhydrochlorid updates RSS · CI watch RSS
- Kai Henrik Wiborg Lange portfolio CI
Frequently asked questions about lidocainhydrochlorid
What is lidocainhydrochlorid?
Who makes lidocainhydrochlorid?
Is lidocainhydrochlorid also known as anything else?
What development phase is lidocainhydrochlorid in?
Related
- Manufacturer: Kai Henrik Wiborg Lange — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Lidocaine, Xylocaine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing